NXSNext Science
About Next Science
Next Science (ASX:NXS) is a medical technology company developing innovative solutions to help improve surgical outcomes and reduce surgical site infections. The company's primary focus is the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health.
What is NXS known for?
Snapshot
Public AU
Ownership
2012
Year founded
102
Employees
New South Wales, Australia
Head office
Loading Map...
Operations
All Locations
Australia
Products and/or services of Next Science
- XBIO™ technology: Next Science's flagship product is its XBIO™ technology, a platform technology that can be used to develop a range of products to treat and prevent biofilm-based infections.
- XPERIENCE: Designed for use in cleansing and removal of debris, including microorganisms from wounds.
- BLASTX: Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing. While in place, the antimicrobial properties of the gel inhibit the growth of microorganisms in the product.
- SURGX: Sterile Antimicrobial Gel conforms to the postoperative wound. The gel provides a moist wound environment conducive to healing.
- Bactisure: Wound Lavage is used to remove debris, including microorganisms, from wounds using pulsed lavage. It is a clear, colourless and low-odour solution.
Next Science executive team
- Dr. Matthew Franco MynttiFounder & CTO
- Mr. Jon SwansonChief Strategy Officer
- Daniel CanonVice President of Operations
- Francoise DixonHead of Investor Relations
- Mr. Robert BellSenior Vice President of North American Sales
- Ms. Gillian Maria Nairn AGIA, B.A., L.L.B., L.L.M., MAICDCompany Secretary